Bayer

Inching closer to being unshackled

30/06/26 -"The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even the decision on Bayer’s $7.25bn settlement ..."

PDF page sample
Pages
71
Language
English
Published on
30/06/26
Download
You may also be interested by these reports :
30/06/26
The recent US Supreme Court decision in the Roundup litigations, went in favour of Bayer, and brings the firm very close to ending this chapter. Even ...
24/06/26
Rather than trying to figure out who will win the obesity race, why not bet on more defensive upstream API production?
23/06/26
Our estimates for 2026 and 2027 are significantly affected by net financial expenses. The firm raised $5.5bn to fund the Merus acquisition, which is ...
19/06/26
Evaluating Pharma’s Defences

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO